CLINICAL TRIALS PROFILE FOR HYDROCHLOROTHIAZIDE; IRBESARTAN
✉ Email this page to a colleague
All Clinical Trials for Hydrochlorothiazide; Irbesartan
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00095394 ↗ | Irbesartan/Hydrochlorothiazide (HCTZ) Combination Therapy as First Line Treatment for Severe Hypertension | Completed | Sanofi | Phase 3 | 2004-09-01 | The purpose of this clinical research is to learn if severe hypertension can be better controlled by initially treating with a combination of drugs (Irbesartan/HCTZ), in patients who are unlikely to achieve blood pressure (B/P) control with only one drug. In addition, the study will also evaluate the safety and tolerability of the drugs. |
| NCT00095394 ↗ | Irbesartan/Hydrochlorothiazide (HCTZ) Combination Therapy as First Line Treatment for Severe Hypertension | Completed | Bristol-Myers Squibb | Phase 3 | 2004-09-01 | The purpose of this clinical research is to learn if severe hypertension can be better controlled by initially treating with a combination of drugs (Irbesartan/HCTZ), in patients who are unlikely to achieve blood pressure (B/P) control with only one drug. In addition, the study will also evaluate the safety and tolerability of the drugs. |
| NCT00095550 ↗ | Irbesartan/Hydrochlorothiazide (HCTZ) Combination Therapy for Patients With Moderate Hypertension | Completed | Sanofi | Phase 3 | 2004-10-01 | The purpose of this clinical research is to learn if moderate hypertension can be better controlled by initially treating with a combination of drugs (Irbesartan/HCTZ), in patients who are unlikely to achieve blood pressure (B/P) control with only one drug. In addition, the study will also evaluate the safety and tolerability of the drugs. |
| NCT00095550 ↗ | Irbesartan/Hydrochlorothiazide (HCTZ) Combination Therapy for Patients With Moderate Hypertension | Completed | Bristol-Myers Squibb | Phase 3 | 2004-10-01 | The purpose of this clinical research is to learn if moderate hypertension can be better controlled by initially treating with a combination of drugs (Irbesartan/HCTZ), in patients who are unlikely to achieve blood pressure (B/P) control with only one drug. In addition, the study will also evaluate the safety and tolerability of the drugs. |
| NCT00110422 ↗ | Irbesartan in the Treatment of Hypertensive Patients With Metabolic Syndrome | Completed | Sanofi | Phase 4 | 2005-11-01 | The purpose of this clinical research study is to learn if irbesartan is superior to hydrochlorothiazide relative to effects on insulin sensitivity and glucose metabolism in hypertensive patients with metabolic syndrome. |
| NCT00110422 ↗ | Irbesartan in the Treatment of Hypertensive Patients With Metabolic Syndrome | Completed | Bristol-Myers Squibb | Phase 4 | 2005-11-01 | The purpose of this clinical research study is to learn if irbesartan is superior to hydrochlorothiazide relative to effects on insulin sensitivity and glucose metabolism in hypertensive patients with metabolic syndrome. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Hydrochlorothiazide; Irbesartan
Condition Name
Clinical Trial Locations for Hydrochlorothiazide; Irbesartan
Trials by Country
Clinical Trial Progress for Hydrochlorothiazide; Irbesartan
Clinical Trial Phase
Clinical Trial Sponsors for Hydrochlorothiazide; Irbesartan
Sponsor Name
